1. The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis 
Pamela Samson, MD, Aalok Patel, BS, Cliff G. Robinson, MD, Daniel Morgensztern, MD, Su-Hsin Chang, PhD, Graham A. Colditz, MD, Saiama Waqar, MD, Traves D. Crabtree, MD, A. Sasha Krupnick, MD, Daniel Kreisel, MD, G. Alexander Patterson, MD, Bryan F. Meyers, MD, MPH, Varun Puri, MD, MSCI 
The Annals of Thoracic Surgery 
Volume 100, Issue 6, Pages (December 2015)
DOI: /j.athoracsur
Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
Consolidated Standards of Reporting Trials flowchart demonstrates non-small cell lung cancer (NSCLC) patient selection criteria and propensity matched analysis. ∗CR and CRS patients were matched by age, gender, race, income, rural vs urban status, year of diagnosis, Charlson-Deyo score, tumor size, and facility type (academic vs nonacademic). †Subgroup analyses with academic and nonacademic CR and CRS patients were matched on age, gender, race, income, rural vs urban status, year of diagnosis, Charlson-Deyo score, and tumor size. ‡Nonacademic CR and CRS patients were matched on age, gender, race, income, rural vs urban status, year of diagnosis, Charlson-Deyo score, and tumor size. ⋄Academic and nonacademic CRS patients were matched on age, gender, race, income, rural vs urban status, year of diagnosis, Charlson-Deyo score, and tumor size.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
Two-way sensitivity analysis varying the probability of surgical survival after pulmonary resection in stage IIIA non-small cell lung cancer from 88% to 98% and the cost of 30-day hospitalization charges from $50,000 to $250,000. Willingness to pay was set at a conventional threshold of $50,000. For propensity-matched patients who received chemotherapy and radiotherapy (CR; blue) and those who received chemotherapy, radiotherapy, and surgical resection (CRS; red), the 30-day mortality rate was 2.2%, and the base cost of 30-day mortality was $55,513. This figure indicates that even with decreases in 30-day surgical survival and increases in associated costs, CRS dominates the decision model over CR for these clinical variations.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions

4. Fig 3
Cost-effectiveness acceptability curve with a willingness-to-pay threshold varying from $0 to $50,000. A total of 1,000 iterations of chemotherapy and radiotherapy (CR, blue line) vs chemotherapy, radiotherapy, and surgical resection (CRS, red line) for propensity-matched stage IIIA non-small cell lung cancer patients were run in a Monte Carlo simulation, using survival inputs from the National Cancer Data Base and Medicare allowable costs. At a willingness-to-pay threshold of $18,000, surgical resection begins to dominate the model choices. At a willingness-to-pay threshold of $25,000, 100% of model patient simulations favor CRS over CR.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions

5. Supplementary Figure 1
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions